Cannabis acts on a signalling network that the human body already has, called the endocannabinoid system. This part covers five topics. It tests the popular claim that the system is the “master regulator of the body’s balance”. It explains a theory that some illnesses come from too little endocannabinoid signalling. It also covers the system outside the brain, tolerance with heavy use, and why people respond so differently to the same cannabis.
A short recap of how the system works:
- Two receptors. CB1 is found mainly in the brain and nerves, and it causes the high. CB2 is found mainly in immune cells, and it does not cause a high.
- Two messengers the body makes itself. These are anandamide and 2-arachidonoylglycerol (2-AG). Cells make them from their own membrane fats at the moment they are needed. They are not stored.
- Two breakdown enzymes. Fatty acid amide hydrolase (FAAH) breaks down anandamide. Monoacylglycerol lipase (MAGL) breaks down 2-AG. Both messengers are usually gone within seconds.
- Plant compounds. Tetrahydrocannabinol (THC) and cannabidiol (CBD) from cannabis act on this system. THC reaches the receptors through the blood and stays much longer than the body’s own messengers.
For you as a grower, this part shows which health claims about cannabis hold up. It also shows why no one can promise how a given flower will feel to a given person.
Translator’s note: In Thailand, cannabis flower (ช่อดอกกัญชา) is a controlled herb. This comes from the Notification of the Ministry of Public Health Re: Controlled Herbs (Cannabis), B.E. 2568, issued under the Thai Traditional Medicine Protection Act B.E. 2542. It has been in force since 26 June 2025. Flower may be sold only with a PT 33 (ภ.ท.33) prescription, for at most 30 days. Advertising and online sale of flower are prohibited.
The researchers cited below are named with the year of their work. Full details are in the References at the end.
This is Part 2. Part 1: The Endocannabinoid System: Receptors, the Body’s Own Cannabinoids and How Cannabis Compounds Act on Them (Part 1 of 2)
1. The “Body’s Balance” Claim, and Where It Breaks Down
The endocannabinoid system is often introduced as the body’s “master regulator of balance”. As a teaching picture, this is defensible. The system mostly dampens signals, and it is found throughout the body. It switches on only when needed. It also appears to soften sudden swings in nerve, immune and metabolic activity.
As a scientific claim, it is much weaker. In physiology, “homeostasis” means keeping one controlled value near a target level (a set point). A correction mechanism pulls the value back when it drifts. Examples are blood pH, core body temperature and blood sugar.
The endocannabinoid system has no single value like that. It works through many small, local feedback loops.
So statements about the system fall into three levels:
| Statement | What it is |
|---|---|
| “It reduces excess messenger release at specific synapses (the gaps between nerve cells).” | A measured finding |
| “It restores balance throughout the body.” | A teaching picture |
| “Supporting your endocannabinoid system will bring you back to health.” | Neither |
What to do with this: Before you repeat or write a claim about this system, sort it into one of these three levels. State only the first kind as fact. This keeps your posts, labels and conversations with patients accurate.
Translator’s note: Advertising of cannabis flower is prohibited in Thailand. Do not use any of these statements to promote flower. For any other product you are allowed to describe, keep to statements of the first kind.
2. Clinical Endocannabinoid Deficiency: A Theory Still Being Tested
Ethan Russo is the researcher who proposed the theory of clinical endocannabinoid deficiency. He first put it forward in 2001. He set it out again in a 2016 paper in Cannabis and Cannabinoid Research.
The idea is that some hard-to-treat conditions might share one underlying cause: too little endocannabinoid signalling. The main examples are:
- migraine;
- fibromyalgia (long-term pain spread across the body);
- irritable bowel syndrome (long-term gut pain with changes in bowel habits).
Russo presents this openly as a theory. He based it on two things. One is genetic overlap between these conditions. The other is comorbidity, which means the conditions often occur together in the same people. He noted that when he first proposed the theory, there was no objective proof and no trial data.
What the evidence supports, and what it does not
The strongest evidence comes from cerebrospinal fluid, the fluid around the brain and spinal cord. People with chronic migraine had lower anandamide in this fluid than people without migraine (the “controls”). The difference was statistically significant.
For fibromyalgia and irritable bowel syndrome, the evidence is more indirect.
The theory has also been criticised for its methods. One critique is a 2020 editorial by Peter S. Cogan titled Practical Considerations of Hypotheses and Evidence in Cannabis Pharmacotherapy: Refining Expectations of Clinical Endocannabinoid Deficiency. It argues that the assumptions behind the theory are weak and that the endocannabinoid system is still vaguely defined.
The fair summary: this is a hypothesis, not an established finding. No named condition has been shown to be caused by endocannabinoid deficiency. Nothing about any particular treatment follows from it.
Translator’s note: If you or a patient has migraine, fibromyalgia or irritable bowel syndrome, do not treat this theory as a reason to use cannabis. Take the question to a licensed practitioner. In Thailand, flower can only be sold on a PT 33 prescription, so a practitioner has to make that decision anyway.
3. The Endocannabinoid System Beyond the Brain
The gut, the gut-brain link and gut bacteria
CB1 is found on the nerve cells in the gut wall (enteric neurons). Endocannabinoid signals play a part in four gut functions:
- motility, meaning how the gut moves food along;
- secretion of digestive fluids;
- visceral sensation, meaning the feelings that come from internal organs;
- barrier function, meaning how well the gut lining keeps gut contents out of the body.
The gut and brain exchange signals all the time through nerves, hormones and the immune system. This two-way link is called the gut-brain axis. The endocannabinoid system plausibly sits where these routes meet. However, most of the detailed evidence comes from animal studies.
The link with the microbiome (the bacteria living in the gut) is newer and much less certain. Wang, Guo, Mao and Chen reviewed it in 2025. They describe three proposed links:
- gut bacteria making molecules that resemble endocannabinoids;
- short-chain fatty acids (made when gut bacteria break down fibre) changing how much of the system’s enzymes cells produce;
- effects on the gut lining’s barrier.
The authors are direct about the limits. Most of this work is observational: it shows that things occur together, not that one causes the other. The area is promising but preliminary. It is not a basis for health conclusions about any one person.
Immune tissue, skin, bone and reproductive tissue
Immune tissue. White blood cells carry CB2, so endocannabinoid signals take part in immune control. This includes cytokine release (cytokines are signalling proteins that immune cells use to coordinate). It also includes cell migration, meaning immune cells moving to where they are needed. The direction of the effect varies with the cell type and the situation. So the claim that “cannabinoids suppress inflammation” is an oversimplification.
Skin. In 2009, Bíró and colleagues described an endocannabinoid system in the skin. It involves keratinocytes (the main cells of the outer skin) and sebaceous gland cells (the cells that make skin oil). It also involves sensory nerve endings and the immune cells that live in the skin.
Bone. In 2019, Ehrenkranz and Levine described CB2 as the main cannabinoid receptor in bone. CB1 is linked to the sympathetic nerves that reach the bone. Sympathetic nerves are part of the nervous system that runs automatic body functions. The authors say human studies are limited. The clinical relevance of cannabis effects on bone is unknown.
Reproductive tissue. In 2019, Walker, Holloway and Raha reported parts of the endocannabinoid system in four places. These are the ovary, the endometrium (the lining of the womb), the oviduct (the tube from the ovary to the womb) and the myometrium (the muscle wall of the womb). They note that most of this knowledge comes from in vitro work (cells in a laboratory dish) and from animal studies.
| Tissue system | Reasonably established | Not established |
|---|---|---|
| Immune system | White blood cells carry the receptors | Consistent results in humans |
| Gut bacteria | Links seen together; plausible mechanisms | Cause and effect; whether results apply to humans |
| Skin, bone, reproductive tissue | Where the receptors and enzymes are | Human evidence for how they work |
What to do with this: When you see a claim about cannabis and the gut, skin, bone or fertility, check which column of this table it belongs in. If it rests on the right-hand column, ask for a human study before you believe it or repeat it. Receptors found in a tissue show only that the system is present there. They do not show that a product works.
Translator’s note: For what cannabis creams and balms can and cannot do, see Cannabis on the Skin. Receptors in reproductive tissue say nothing about safety in pregnancy. For that evidence, see Cannabis, Pregnancy and Breastfeeding.
4. Tolerance and Receptor Loss With Heavy Use
Tolerance means the same dose gives less effect over time. One cause is receptor downregulation, where cells reduce the number of receptors on their surface.
Hirvonen and colleagues studied this in 2012 using positron emission tomography (PET). PET is a brain scan that uses a small amount of a radioactive tracer to show where a target molecule sits.
They scanned people who had smoked cannabis every day for a long time. These people had fewer CB1 receptors in the cortex, the outer layer of the brain. The longer they had used cannabis, the larger the drop.
What the recovery data show
The recovery finding is just as important, but it is quoted less often. The same people stayed on a closed research ward, where researchers checked continuously that they used no cannabis. After about four weeks, their CB1 receptor numbers had returned to normal levels.
A 2018 systematic review of human studies by Marco Colizzi and Sagnik Bhattacharyya reached a similar conclusion. Tolerance develops with regular use. Stopping is linked to at least partial reversal.
These results have limits:
- the 2012 study was small;
- it involved heavy daily users only;
- the changes were in some brain regions, not across the whole brain;
- tolerance to different effects does not fade at the same speed.
What the data do support is general. With long-term heavy use, the receptors adapt. This change is real and measurable, and much or all of it can reverse.
Translator’s note: The four-week figure comes from one small study of heavy daily users. Do not treat it as a personal schedule. If you are a patient with a PT 33 prescription and the same dose seems to work less, tell your prescriber instead of raising the dose yourself. The prescriber can review the dose and the reasons behind the change.
5. Why People Respond So Differently
Starting receptor numbers differ. People have different numbers of receptors, and so do different brain regions within the same person. Past use changes these numbers.
Past use also changes the response in other ways: through what the person expects, the setting they are used to, and how familiar the effect feels. These are hard to separate from the drug’s chemical action.
Genes differ. The best-studied example is a common variant in the gene for the enzyme FAAH, which breaks down anandamide. It is called C385A. It is a “missense” variant: a one-letter change in the DNA that swaps one building block of the enzyme.
Dincheva and colleagues reported on this variant in 2015. In mice and in humans, it was linked to changes in how the front of the brain works with the amygdala, a region involved in fear and emotion. This fits with lower enzyme activity and higher anandamide levels.
Boileau and colleagues, also in 2015, found that the same variant changes how a PET tracer for FAAH binds in the brain. This confirms that the variant changes the amount of enzyme available in the living human brain.
Each of these is a group-level effect, meaning it shows up when groups of people are compared. None of these factors can be measured in ordinary practice. None of them predicts what a given person will experience. Science explains why people differ much better than it predicts how any one person will respond.
What to do with this: If you supply flower to licensed shops or clinics, describe it by the THC and CBD figures on a laboratory certificate of analysis. Do not promise how it will feel. The lab figures can be measured, but a person’s response cannot be predicted. If someone offers a gene test that claims to predict your response to cannabis, remember that the research above does not support predictions for individuals.
Questions and corrections are welcome below this topic. Which point surprised you most: how many body tissues outside the brain carry this system, or how much of the evidence there is still preliminary? Questions about the backwards direction of the signal and about how CBD works belong under Part 1. If you work in physiology, pharmacology, nursing or laboratory science, your corrections and additions are especially welcome.
This article is part of the Asiannabis Community educational series on medical cannabis. It is general information, not medical advice. Treatment decisions belong with a licensed practitioner. The content is for education in places where medical cannabis is legally permitted.
References
- Ethan Russo. Theory of clinical endocannabinoid deficiency, first proposed 2001; paper in Cannabis and Cannabinoid Research, 2016.
- Peter S. Cogan. Practical Considerations of Hypotheses and Evidence in Cannabis Pharmacotherapy: Refining Expectations of Clinical Endocannabinoid Deficiency, editorial, 2020.
- Wang, Guo, Mao and Chen. Review, Frontiers in Cellular and Infection Microbiology, 2025.
- Bíró and colleagues. Trends in Pharmacological Sciences, 2009.
- Ehrenkranz and Levine. Journal of Clinical Endocrinology & Metabolism, 2019.
- Walker, Holloway and Raha. Journal of Ovarian Research, 2019.
- Hirvonen and colleagues. Molecular Psychiatry, 2012.
- Marco Colizzi and Sagnik Bhattacharyya. Systematic review of human evidence, 2018.
- Dincheva and colleagues. Nature Communications, 2015.
- Boileau and colleagues. Journal of Cerebral Blood Flow & Metabolism, 2015.